CBT
Cabot Corporation
NYSEUSDEQUITY
Basic Materials
DELAYED
Last price
85.00
▲ 0.07 (0.08%)
MARKET · —
Price
Open
84.93
Prev close
84.93
Day high
86.05
Day low
84.32
Volume
250.88K
Market cap
$4.40B
P/E (TTM)
23.80
52W range
58.33 – 94.53
Trailing performance
Returnvs SPY
1W
-3.06%
-1.7%
1M
-4.40%
-8.1%
3M
+8.74%
+5.6%
6M
+12.66%
+1.6%
YTD
+28.53%
+16.2%
1Y
+7.52%
-12.5%
3Y
+24.33%
-49.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$4.40B
Enterprise value$5.57B
Revenue (TTM)$3.63B
Gross profit$880.00M
EBITDA$736.00M
Net income$187.00M
EPS (TTM)$3.58
Free cash flow$258.25M
Total cash$250.00M
Total debt$1.29B
Book value / share$31.09
Shares outstanding51.63M
Float50.86M
Short % of float9.95%
Dividend yield2.17%
Beta (5Y)0.84
Valuation & profitability ratios
Trailing P/E23.80
Forward P/E12.21
PEG ratio1.00
Price / sales—
Price / book2.74
EV / revenue1.53
EV / EBITDA7.56
Gross margin24.22%
Operating margin14.26%
Profit margin5.23%
Return on equity13.35%
Return on assets8.90%
Debt / equity74.39
Current ratio1.47
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $3.71B | $3.99B | $3.93B | $4.32B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $0 | $0 | $445.00M | $209.00M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $0 | $0 | $445.00M | $209.00M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.66 | 1.67 | +0.7% |
| Mar 2026 | 1.47 | 1.61 | +9.8% |
| Dec 2025 | 1.38 | 1.53 | +10.8% |
| Sep 2025 | 1.68 | 1.70 | +1.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.52 | 5 | $913.02M | +1.6% |
| Next quarter | 1.51 | 2 | $860.00M | +1.3% |
| Current year | 6.34 | 6 | $3.66B | -1.4% |
| Next year | 6.98 | 6 | $3.78B | +3.2% |
Analyst targets & ownership
Mean target$91.33
High target$100.00
Low target$78.00
Implied upside7.45%
Analyst count6
ConsensusBUY
Strong buy / Buy0 / 2
Hold3
Sell / Strong sell0 / 1
Held by insiders1.34%
Held by institutions106.37%
Institutions holding530
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
1
91.92K shares
Sell transactions
1
91.92K shares
Net transactions
+2
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
693.92K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 7, 26 | KEOHANE SEAN D Chief Executive Officer |
CONVERSION | 91.92K | $5.72M | Direct |
| Aug 7, 26 | KEOHANE SEAN D Chief Executive Officer |
SELL | 91.92K | $7.94M | Direct |
| Jan 8, 26 | WILSON FRANK ANDERS Director |
STOCK | 2.30K | $0 | Direct |
| Jan 8, 26 | ARNOLD CYNTHIA A Director |
STOCK | 2.30K | $0 | Direct |
| Jan 8, 26 | YAN CHRISTINE YINGLI Director |
STOCK | 2.30K | $0 | Direct |
| Jan 8, 26 | VANLANCKER THIERRY F J Director |
STOCK | 2.30K | $0 | Direct |
| Jan 8, 26 | MORROW MICHAEL M. Director |
STOCK | 2.30K | $0 | Direct |
| Jan 8, 26 | DEL GROSSO DOUGLAS G Director |
STOCK | 2.30K | $0 | Direct |
| Jan 8, 26 | KIRBY WILLIAM C Director |
STOCK | 486 | $0 | Direct |
| Jan 8, 26 | WILLIAMS MICHELLE ELIZABETH Director |
STOCK | 2.30K | $0 | Direct |
| Jan 8, 26 | NATHOO RAFFIQ A Director |
STOCK | 2.30K | $0 | Direct |
| Jan 8, 26 | ENRIQUEZ CABOT JUAN Director |
STOCK | 486 | $0 | Direct |
| Dec 31, 25 | NATHOO RAFFIQ A Director |
CONVERSION | 3.38K | $224.28K | Direct |
| Dec 3, 25 | MASTERSON WILLIAM F III Officer |
STOCK | 3.49K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARNOLD CYNTHIA A |
Director | 19.62K | Stock Award(Grant) |
ENRIQUEZ CABOT JUAN |
Director | 41.53K | Stock Award(Grant) |
KALITA KAREN A |
General Counsel | 45.82K | Stock Award(Grant) |
KALKSTEIN HOBART C |
Officer | 60.33K | Stock Award(Grant) |
KEOHANE SEAN D |
Chief Executive Officer | 418.40K | Conversion of Exercise of derivative security |
KIRBY WILLIAM C |
Director | 27.69K | Stock Award(Grant) |
MCLAUGHLIN ERICA |
Chief Financial Officer | 77.78K | Stock Award(Grant) |
MORROW MICHAEL M. |
Director | 22.30K | Stock Award(Grant) |
WOLFGRUBER MATTHAIS L |
Director | 22.10K | Stock Award(Grant) |
ZHU JEFF JI |
Officer | 85.34K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
85.98
-1.14% from price
SMA 20
86.96
-2.04% from price
SMA 50
88.11
-3.31% from price
SMA 100
83.81
+1.42% from price
SMA 200
76.47
+11.41% from price
EMA 12
86.03
-1.20% from price
EMA 26
86.80
-2.07% from price
EMA 50
86.47
-1.71% from price
RSI (14)
45.3
Neutral
MACD (12,26,9)
-0.77
Hist -0.24
ATR (14)
3.12
3.66% of price
Realised vol 30D
35.9%
Annualised
Bollinger upper
91.54
20, 2σ
Bollinger lower
82.39
20, 2σ
50 / 200 cross
Golden
88.11 vs 76.47
Trend bias
Above 200
+11.41%
Risk profile
Beta vs SPY
0.64
Less volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
35.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-29.2%
Peak to trough
Max drawdown 5Y
-49.8%
Peak to trough
ATR 14
3.12
3.66% of price
Beta (reported)
0.84
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.11
Call-heavy session
Put / call open interest
0.59
Positioning, not flow
Max pain
80.00
-6.1% from spot
ATM implied vol
29.8%
Nearest strike to spot
Skew (10% OTM)
+3.3%
Puts bid over calls
Call volume
126
Contracts, this expiry
Put volume
14
Contracts, this expiry
Heaviest call OI
80.00
94 contracts
Heaviest put OI
95.00
20 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Cabot Corporation Prices $350 Million 4.950% Senior Notes Due 2029
GlobeNewswire · 10d ago
Cabot (CBT) Q3 2026 Earnings Call Transcript
Motley Fool · 12d ago
CBT Q3 Earnings Beat Estimates on Performance Chemicals Strength
Zacks · 12d ago
UBS Adjusts Price Target on Cabot to $92 From $97, Maintains Neutral Rating
MT Newswires · 17d ago
Cabot Q3 Earnings Call Highlights
MarketBeat · 18d ago
Cabot Corp (CBT) (Q3 2026) Earnings Call Highlights: Strong Performance Chemicals Growth and ...
GuruFocus.com · 18d ago
Cabot Corporation Q3 2026 Earnings Call Summary
Moby · 18d ago
Cabot (CBT) Tops Q3 Earnings and Revenue Estimates
Zacks · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.